Pharma Pioneer

What Does Lisocabtagene Maraleucel Do?

10 May 2024
3 min read

Lisocabtagene maraleucel, marketed under the brand name Breyanzi, is a revolutionary immunotherapy medication developed by Bristol-Myers Squibb. It targets CD19-positive B-cell lymphoma cells, a type of white blood cell that becomes cancerous in large B-cell lymphoma. The drug is classified under the miscellaneous antineoplastics and is used to treat adult patients with relapsed or refractory large B-cell lymphoma after at least two other cancer treatments have failed.

ShareLisocabtagene maraleucel represents a significant advancement in the field of cellular immunotherapy, offering a new treatment option for patients with limited alternatives.

Mechanism of Action of Lisocabtagene Maraleucel

Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T-cell immunotherapy. It works by using the patient's own white blood cells, which are collected through a process called leukapheresis. These cells are then genetically modified in the laboratory to express a chimeric antigen receptor (CAR) that targets CD19, a protein found on the surface of certain B-cell lymphoma cells. Once infused back into the patient, these modified T-cells can identify and destroy the cancerous B-cells, offering a targeted approach to cancer treatment.

How to Use Lisocabtagene Maraleucel

Lisocabtagene maraleucel is administered intravenously as a suspension in authorized hospitals or clinics by specially trained healthcare professionals. The treatment process begins with leukapheresis to collect the patient's T-cells. These cells are then sent to a laboratory where they are manufactured into lisocabtagene maraleucel. The patient will also undergo pre-treatment with chemotherapy approximately 2 to 7 days before the infusion of lisocabtagene maraleucel to prepare the body for the treatment. The actual infusion of the drug may take several hours, and patients are advised to stay near the hospital or clinic for at least 4 weeks after treatment.

Side Effects of Lisocabtagene Maraleucel

Lisocabtagene maraleucel can cause a range of side effects, some of which can be severe. The most common but serious side effect is cytokine release syndrome (CRS), which presents with symptoms such as fever, chills, dizziness, confusion, vomiting, diarrhea, rapid heartbeats, and extreme fatigue. Other serious side effects may include problems with speech, confusion, memory problems, decreased consciousness, tremors, seizures, and signs of infection. Common side effects include headache, dizziness, nausea, vomiting, stomach pain, diarrhea, constipation, irregular heartbeats, cough, difficulty breathing, swelling, and bone, joint, or muscle pain.

Drug Interactions with Lisocabtagene Maraleucel

Patients receiving lisocabtagene maraleucel should inform their doctor about all medications they are currently taking, including prescription and over-the-counter drugs, vitamins, and herbal products. Certain medications may affect the efficacy of lisocabtagene maraleucel or increase the risk of side effects. It is crucial to follow the healthcare provider's instructions regarding the use of other medications during and after the treatment with lisocabtagene maraleucel.

In conclusion, lisocabtagene maraleucel is a groundbreaking treatment for adult patients with large B-cell lymphoma who have exhausted other treatment options. Its targeted immunotherapy approach offers a new path forward in the fight against this aggressive form of cancer. However, due to its complex administration process and potential for severe side effects, patients must be closely monitored by healthcare professionals throughout the treatment journey.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can keep abreast of the latest research and development advances of all drugs anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 应用程序

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Adcentrx Therapeutics Gains China's NMPA IND Approval for ADRX-0706, a Nectin-4 Antibody-Drug Conjugate for Advanced Solid Tumors
Latest Hotspot
3 min read
Adcentrx Therapeutics Gains China's NMPA IND Approval for ADRX-0706, a Nectin-4 Antibody-Drug Conjugate for Advanced Solid Tumors
10 May 2024
Adcentrx Therapeutics has received IND approval from China's NMPA for ADRX-0706, a new Nectin-4 antibody-drug conjugate designed to treat advanced solid tumors.
Read →
What Does Avibactam / Ceftazidime Do?
Pharma Pioneer
3 min read
What Does Avibactam / Ceftazidime Do?
10 May 2024
Avibactam / Ceftazidime, commercially known as Avycaz, is an antibiotic combination developed by AstraZeneca.
Read →
What ADC-related progress will Mabwell (Shanghai) Bioscience reveal at the ASCO conference?
Hot Spotlight
7 min read
What ADC-related progress will Mabwell (Shanghai) Bioscience reveal at the ASCO conference?
10 May 2024
At the upcoming ASCO conference, Mabwell (Shanghai) Bioscience will present the Phase I/II clinical study results of 9MW2821 for several advanced solid tumors through an oral report.
Read →
What is Age-standardized Rate?
"What" Series
2 min read
What is Age-standardized Rate?
10 May 2024
Age-standardized rate refers to a statistical measure that allows for the comparison of health-related rates, such as disease incidence or mortality rates, between populations with different age structures.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.